Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Comparator 1

Phase 1Small molecule

Comparator 1 is one of 47 small molecule programs targeting Psoriasis. It is currently in Phase 1.

2

Indications

4

Total Trials

2

Active Trials

46

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

DapagliflozinNot yet recruiting

PsoriasisPreclinical

Active, not recruiting

DapagliflozinPhase 1

Not yet recruiting

Competition

Competitive Landscape

107 competitors in Psoriasis

#DrugCompanyPhaseTrials

Daliresp

Zasocitinib

D-2570

IInventisBio Co., Ltd

TAK-279

Ponvory

VVanda Pharmaceuticals

SYHX1901

CCSPC Ouyi Pharmaceutical Co., Ltd.

Vunakizumab (IL-17A Inhibitor)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

SHR-1314

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

HS-10374

Jiangsu Hansoh Pharmaceutical Co., Ltd.

ICP-488

BBeijing InnoCare Pharma Tech Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dapagliflozin2 trials

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study

Not yet recruiting·AAJU Pharm Co., Ltd.·Phase 1·NCT07044765·32 enrolled

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults

Not yet recruiting·AAJU Pharm Co., Ltd.·Phase 1·NCT07034781·50 enrolled

Psoriasis1 trial

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Withdrawn· AbbVie logo

AbbVie··NCT04799990

Alcohol Intoxication1 trial

Possible Effects of Energy Drink Ingestion on Perceived Alcohol Intoxication

Unknown status·MMedical University of Vienna·N/A·NCT01350089·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Comparator 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Comparator 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Comparator 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AbbVie

Related News